Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
27/11/201806:00Business WireAcceleron to Host Conference Call & Webcast to Review MEDALIST & BELIEVE Phase 3 Trial Presentations of Luspatercept at the 6...NASDAQ:XLRNAcceleron Pharma Inc
26/11/201806:00Business WireAcceleron to Participate in Two Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
07/11/201806:00Business WireAcceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart As...NASDAQ:XLRNAcceleron Pharma Inc
01/11/201808:01Business WireAcceleron Announces that Phase 3 Results from the MEDALIST & BELIEVE Trials of Luspatercept will be Presented at the 60th Ame...NASDAQ:XLRNAcceleron Pharma Inc
30/10/201815:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
30/10/201815:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
30/10/201815:05Business WireAcceleron Reports Third Quarter 2018 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
23/10/201806:00Business WireAcceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018NASDAQ:XLRNAcceleron Pharma Inc
16/10/201806:00Business WireAcceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York C...NASDAQ:XLRNAcceleron Pharma Inc
10/10/201810:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
27/09/201806:00Business WireAcceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle SocietyNASDAQ:XLRNAcceleron Pharma Inc
04/09/201813:43Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
04/09/201806:00Business WireAcceleron to Participate in Three Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
31/08/201818:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
02/08/201815:05Business WireAcceleron Reports Second Quarter 2018 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
26/07/201806:00Business WireAcceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018NASDAQ:XLRNAcceleron Pharma Inc
23/07/201806:00Business WireAcceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease...NASDAQ:XLRNAcceleron Pharma Inc
12/07/201806:00Business WireAcceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular DystrophyNASDAQ:XLRNAcceleron Pharma Inc
10/07/201816:28Dow Jones NewsHealth Care Shares Move Higher as Focus Shifts to Earnings -- Health Care RoundupNASDAQ:XLRNAcceleron Pharma Inc
09/07/201817:36Dow Jones NewsCelgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results -- UpdateNASDAQ:XLRNAcceleron Pharma Inc
09/07/201817:20Dow Jones NewsCelgene and Acceleron Announce Positive Results From Blood-Disorder Drug TrialsNASDAQ:XLRNAcceleron Pharma Inc
09/07/201815:52Business WireCelgene & Acceleron Announce Luspatercept Achieved Primary & All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in ...NASDAQ:XLRNAcceleron Pharma Inc
05/07/201815:46Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
05/07/201815:30Business WireAcceleron Appoints Robert K. Zeldin, M.D., Chief Medical OfficerNASDAQ:XLRNAcceleron Pharma Inc
28/06/201815:30Business WireCelgene & Acceleron Announce Luspatercept Achieved Primary & Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Pat...NASDAQ:XLRNAcceleron Pharma Inc
26/06/201806:00Business WireAcceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve SocietyNASDAQ:XLRNAcceleron Pharma Inc
15/06/201806:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of t...NASDAQ:XLRNAcceleron Pharma Inc
04/06/201806:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018...NASDAQ:XLRNAcceleron Pharma Inc
22/05/201806:00Business WireAcceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
17/05/201808:21Business WireAcceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology AssociationNASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN